Information Provided By: 
Fly News Breaks for April 8, 2015
EXAS
Apr 8, 2015 | 07:53 EDT
After surveying 102 high-FIT/FOBT prescribing primary care and ob/gyn physicians who have been prescribing ColoGuard for at least four months, JMP Securities says that utilization of Exact Sciences' ColoGuard is increasing at a rapid pace. The firm adds that doctors are becoming more optimistic regarding the potential long-term penetration of ColoGuard into the market. The firm reiterates a $27 price target and Outperform rating on the shares.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
